This Phase II trial is evaluating combinations of targeted therapies (enoblituzumab, retifanlimab and tebotelimab) in people with recurrent or metastatic squamous cell carcinoma of the head and neck.
This trial is treating patients with squamous cell carcinoma of the head and neck.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This is a non-randomised trial with two experimental arms. Participants in Experimental Arm 1 will receive Enoblituzaumab (15mg/kg) every 2 weeks in combination with retifanlimab (375mg) every 3 weeks for up to 35 cycles. Participants in Experimental Arm 2 will receive Enoblituzumab (15mg/kg) every 3 weeks plus tebotelimab (600mg) every 3 weeks for up to 35 cycles.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More